Board of directors

Garry Watts was appointed to the Board as a Non-Executive Director and Senior Independent Director on 2 March 2020.

Garry brings to the Company extensive Board-level experience gained in the healthcare sector. He was a non-executive member of the Board of the UK Medicines and Healthcare Regulatory Products Agency for over 15 years. He was previously Non-Executive Director of Coca Cola Europacific Partners plc, Chair of Spire Healthcare Group plc, BTG plc, and Foxtons plc, CEO of SSL International plc, Finance Director at Medeva plc and a Director of Celltech Group plc.

Garry is a Chartered Accountant and former partner at KPMG and is a fellow of the Institute of Chartered Accountants in England and Wales.

Jonathan Emms was appointed to the Board as Chief Operating Officer on 2 September 2019 and became Chief Executive Officer in January 2025.

Jonathan brings significant senior-level experience of the global pharmaceutical industry to the Group. Previously, he was Chief Commercial Officer for Pfizer’s Internal Medicines organisation, where he led commercial activities across the company’s global operations.

He held a number of senior positions at Pfizer, including Head of Marketing for its Global Established Pharmaceutical Business and Head of Marketing for Specialty Care, Europe, and oversaw the UK launch of Spiriva® under the company’s co-promotion agreement with Boehringer Ingelheim. He was also Country Manager in the UK, Pfizer’s largest affiliate outside the United States, where he had responsibility for manufacturing, research and commercial operations and during his tenure was elected President of the Association of the British Pharmaceutical Industry (ABPI).

Prior to his time at Pfizer, Jonathan held several roles of increasing responsibility at GSK, where he gained significant respiratory experience, including leading the UK launch of Serevent® in COPD. He holds a BSc in Materials Technology from Coventry University, UK.

Sarah Duncan was promoted to Chief Financial Officer of NIOX on 14 May 2025.

She joined the company in 2018 as Group Finance Manager and took on the additional role of Company Secretary in November 2020.

Sarah was promoted to Group Financial Controller in April 2024, having contributed to the Group’s financial management, reporting, and governance functions over several years. She brings solid experience in finance and compliance and continues to play a key role in supporting the Group’s operations and strategic objectives.

She holds a BA in Business and Information Management from the University of Sheffield and is a member of the Institute of Chartered Accountants of England and Wales.

Sharon Curran was appointed to the Board as an Independent Non-Executive Director on 8 February 2018.

Sharon brings to the Company extensive commercial and launch experience in pharmaceuticals and devices across Europe, US, Asia and emerging markets. Sharon has held numerous senior operational and strategic roles at Eli Lilly, Abbott and most recently as VP Global Marketing and Commercial Operations at AbbVie (US) leading their global specialty franchise and development of global commercial and launch capabilities.

She is currently a Non-Executive Director with Norgine Pharma (Spinnaker TopCo Ltd) and Abacus Medicine A/S, Denmark.

Sharon holds an Executive MSc in Business Administration from Trinity College Dublin, BSc in Biotechnology from Dublin City University and a Diploma in Company Management from the Institute of Directors.

Robert Naylor was appointed to the Board as an Independent Non-Executive Director on 1 July 2024.

Robert is Lead Fund Manager at Achilles Investment Company Limited, focused on maximising portfolio value through constructive engagement. He is a Non-Executive Director of Renalytix plc, developer of the only FDA-approved and Medicare-reimbursed prognostic test for early-stage chronic kidney disease risk assessment, Life Science REIT plc and Aquila European Renewables plc.

Previously, he served on the board of The PRS REIT plc, a FTSE 250 company managing around 5,400 family homes, whose assets were sold with the equity provided by four local authority pension schemes. He was also Chairman of Hipgnosis Songs Fund Limited, leading its sale to funds advised by Blackstone, and Chairman of Round Hill Music Royalty Fund Limited, overseeing its sale to Concord. Earlier, he was CEO and co-founder of Intuitive Investments Group plc, providing exposure to high-growth technology and life sciences businesses.

Robert began his career at Ernst & Young, qualifying as a Chartered Accountant.

Nicholas Mills was appointed to the Board as a Non-Independent Non-Executive Director on 13 November 2020.

Nicholas joined Harwood Capital LLP in 2019 after spending 5 years at Gabelli Asset Management in New York and currently acts as a fund manager. At Gabelli, he acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds. He has a Bachelor of Science Degree from Boston College’s Carroll School of Management.

He is currently a Non-Executive Director with Hargreaves Services plc, Trifast plc, and E Energy plc.